Dominique Couanet-Valteau

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 132 publications

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy: the impact of large vertebral irradiation and gonadal damage.

Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy: the impact of large vertebral irradiation and gonadal damage.

Journal: Bone marrow transplantation

Published: April 09, 2026

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Journal: Frontiers in oncology

Published: October 30, 2025

Colorectal cancer screening participation in childhood cancer survivors: a report from the French Childhood Cancer Survivors Study (FCCSS).

Colorectal cancer screening participation in childhood cancer survivors: a report from the French Childhood Cancer Survivors Study (FCCSS).

Journal: International journal of epidemiology

Published: September 21, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers

Published: July 24, 2025

International neuroblastoma risk group consortium: a model of a networking for rare cancers.

International neuroblastoma risk group consortium: a model of a networking for rare cancers.

Journal: Journal of the National Cancer Institute

Published: June 22, 2025

International neuroblastoma risk group consortium: a model of networking for rare cancers.

International neuroblastoma risk group consortium: a model of networking for rare cancers.

Journal: Journal of the National Cancer Institute

Published: June 22, 2025

Leukoencephalopathy, a Frequent Complication After High-Dose Methotrexate in Treatment of Osteosarcoma.

Leukoencephalopathy, a Frequent Complication After High-Dose Methotrexate in Treatment of Osteosarcoma.

Journal: Pediatric blood & cancer

Published: June 06, 2025

Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study.

Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study.

Journal: Pediatric blood & cancer

Published: January 24, 2025

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 17, 2025

Rationale for irradiation of persisting oligo-skeletal metastases to improve survival of metastatic neuroblastoma patients with a poor response to chemotherapy: A retrospective study.

Rationale for irradiation of persisting oligo-skeletal metastases to improve survival of metastatic neuroblastoma patients with a poor response to chemotherapy: A retrospective study.

Journal: Pediatric blood & cancer

Published: April 29, 2024

Showing 1-12 of 132

Last Updated: 09/26/2026